Ann Rheum Dis

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Published Online First: 19 December 2006. doi:10.1136/ard.2006.060301
Annals of the Rheumatic Diseases 2007;66:798-802
Copyright © 2007 BMJ Publishing Group Ltd & European League Against Rheumatism

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
ard.2006.060301v1
66/6/798    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stassen, P. M
Right arrow Articles by Stegeman, C. A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stassen, P. M
Right arrow Articles by Stegeman, C. A

EXTENDED REPORT

Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide

Patricia M Stassen 1, Jan Willem Cohen Tervaert 2, Coen A Stegeman 1

1 Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
2 Department of Clinical Immunology, University Hospital Maastricht, Maastricht, The Netherlands

Correspondence to:
Correspondence to:
MrsP M Stassen
Department of Nephrology, University Medical Center Groningen, PO box 30001, 9700 RB Groningen, The Netherlands; p.m.stassen{at}int.umcg.nl

Background: Active anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) is commonly treated with cyclophosphamide, a drug with serious side effects, and with corticosteroids.

Objective: To determine the efficacy of a possible alternative drug for cyclophosphamide, oral mycophenolate mofetil (MMF) 1000 mg twice daily and oral prednisolone 1 mg/kg once daily as remission induction treatment.

Methods: 32 consecutive patients with 34 episodes of active vasculitis who could not be treated with cyclophosphamide were diagnosed for a median (range) of 6.0 (0.3–22) years and experienced 4 (0–14) relapses prior to the current episode. Treatment response and relapse-free survival were analysed.

Results: Complete remission (CR) was obtained in 25 (78%) patients, partial remission (PR) in 6 (19%), whereas 1 (3%) patient did not respond. 19 patients relapsed, 13 (52%) after CR, 14 (3–58) months after starting the treatment and 6 (100%) after PR, 6 (2–10) months after starting the treatment. The median relapse-free survival was 16 months, comparable with the interval between the previous relapse and the current MMF-treated relapse (17 (3–134) months). Relapse-free survival at 1, 3, and 5 years was 63%, 38% and 27%, respectively. Patients who had been treated successfully with cyclophosphamide before responded better (CR 84%, relapse 50%) than those who had not (CR 50%, relapse 100%). Minor gastrointestinal side effects and infections occurred frequently. MMF was prematurely discontinued due to adverse effects in two patients.

Conclusion: MMF, in combination with prednisolone, can induce remission in patients with relapses of AAV intolerant to cyclophosphamide.


Abbreviations: AAV, ANCA-assocciated vasculitis; BVAS, Birmingham Vasculitis Activity Score; CR, complete remission; PR, partial remission; MMF, mycophenolate mofetil; WG, Wegener’s granulomatosis




This article has been cited by other articles:


Home page
CJASNHome page
A. D. Salama, H. T. Cook, C. D. Pusey, and R. J. Pepper
A Case of Treated ANCA-Associated Vasculitis with Recurrent Renal Failure
Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(2): 637 - 645.
[Full Text] [PDF]


Home page
JAMAHome page
X. Bosch, A. Guilabert, G. Espinosa, and E. Mirapeix
Treatment of Antineutrophil Cytoplasmic Antibody Associated Vasculitis: A Systematic Review
JAMA, August 8, 2007; 298(6): 655 - 669.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2007 BMJ Publishing Group Ltd & European League Against Rheumatism